NCT04550494: Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations

Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: BRCA+, DNA damage repair mutations, ATM, CDK, IDH
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 2
Drug Category: Misc Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patients must have progressed following at least one standard therapy; Patients with HER2+ breast cancer must have had 2 prior systemic lines of therapy; Patients eligible for a PARP inhibitor by Food and Drug Association (FDA) approvals must have had a prior PARP inhibitor
Exclusions: Patients with prior treatment of talazoparib; Patients with unstable, symptomatic, uncontrolled brain metastases and/or leptomeningeal disease- see trial for details

Comments are closed.

Up ↑